Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan versus valsartan for proteinuria reduction in low-risk membranous nephropathy
ChiCTR2100050967Phase 4Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sacubitril + valsartan and valsartan in membranous glomerulonephritis (MGN) (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoint: 24-hour urine protein. Started Sep 2021; status: recruiting.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
membranous glomerulonephritis (MGN)
Beyond the preview
Go deeper on ChiCTR2100050967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050967.